Right Ventricular Strain in Detecting Subclinical Right Ventricular Systolic Dysfunction in Psoriatic Arthritis Patients: Relation to Serum Endostatin Level

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07046312

Enrollment

Registered

2025-07-01

Start date

2025-07-31

Completion date

2027-04-30

Last updated

2025-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriatic Arthritis (PsA), Subclinical Right Ventricular Systolic Dysfunction

Brief summary

The aim is to assess early right ventricular systolic dysfunction in psoriatic arthritis patients using RV strain echocardiography

Detailed description

Previous studies evaluated RV strain for detection of subclinical RV affection due to PAH in systemic lupus erythematosus. However , to our knowledge , the study of RV strain and its possible association with serum endostatin to detect subclinical right ventricular systolic dysfunction and its relation to PAH in PsA patient is still a novel. Our aim is to assess early right ventricular systolic dysfunction in psoriatic arthritis patients using RV strain Echocardiography. To evaluate serum endostatin as an objective biomarker for Pulmonary arterial hypertension.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

20 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* Psoriatic arthritis patients according to CASPAR criteria * Psoriatic arthritis patients without overt cardiovascular symptoms * Patients with age between 20 to 50 years of age

Exclusion criteria

* Other systemic autoimmune diseases * Patients with a history of known valvular disease, atrial fibrillation or any other arrhythmia , heart failure, ischemic cardiomyopathy severe obstructive pulmonary diseases and metabolic syndrome. * Patients with medical disorders as renal, congenital heart diseases, hematological disorders and cancer patients. * Patients taking certain drugs that have been confirmed to be risk factors for PAH such as appetite suppressant intake drugs (aminorex, fenfluramine derivatives and benfluorex) and chemotherapeutic agents. * Family history of myocardial infarction, cerebrovascular disease or sudden death before the age of 65y in females and 55 y in males.

Design outcomes

Primary

Measure	Time frame	Description
Detecting subclinical right ventricular systolic dysfunction in PsA patients	Up to 24 months	Detecting subclinical right ventricular systolic dysfunction in PsA using 2D strain transthoracic echo and its relation to serum endostatin level

Countries

Egypt

Contacts

Primary ContactDina Maamoun ElHadba, MSc Ain Shams University

DinaElhadba@med.asu.edu01006780166

Outcome results